


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Mary Medical Center - Hobart</p> <p>2. 1500 S. Lake Park Ave. Hobart, IN 46342</p>	<p>In accordance with letter dated November 7, 2022,</p> <p>3. License No.: 13-03459-03 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: January 31, 2026</p> <p>5. Docket No.: 030-31379 Reference No.:</p>
--	--	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 3 millicuries total	D. For use in in-vitro studies.




**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:  
030-31379

Amendment No. 42  
(Corrected Copy)

- |   |  |  |   |
|---|--|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>E. Yttrium-90 permitted by 10 CFR 35.1000</p> | <p>7. Chemical and/or physical form</p> <p>E. Microspheres (Sirtex, Model SIR-Spheres)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>E. 296 millicuries per vial; 2 curies total</p> | <p>9. Authorized use</p> <p>E. For use in permanent manual brachytherapy using Sirtex Model SIR-Spheres yttrium-90 microspheres delivery system as permitted by 10 CFR 35.1000.</p> |
|---|--|--|---|



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:  
030-31379Amendment No. 42  
(Corrected Copy)

CONDITIONS

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.E. may be used or stored at the licensee's facilities located at 1500 S Lake Park Ave., Hobart, Indiana.
- B. Licensed material listed in Subitem Nos. 6.A. through 6.D. may also be used or stored at the licensee's facilities located at 300 W 61st Ave., Hobart, Indiana.
- C. Licensed material listed in Subitem Nos. 6.A. through 6.B may also be used or stored at the licensee's facilities located at 3545 Arbors Blvd., Portage, Indiana.
- D. Licensed material listed in Subitem Nos. 6.A. through 6.B may also be used or stored at the licensee's facilities located at 3800 St. Mary Drive, Valparaiso, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Santosh K. Kar, M.S.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D.,D.O.,etc.)</u> | <u>Material and Use</u>                   |
|---|---|
| Samer Ajam, M.D.                        | 10 CFR 35.200                             |
| Keith Atassi, M.D.                      | 10 CFR 35.200                             |
| Janushi Dalal, M.D.                     | 10 CFR 35.100,10 CFR 35.200               |
| Joseph Danavi, M.D.                     | 10 CFR 35.200                             |
| John W. Gustaitis, Jr., M.D.            | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 |
| Thomas M. Hoess, M.D.                   | 10 CFR 31.11,10 CFR 35.100,10 CFR 35.200  |
| Abdul Kawamleh, M.D.                    | 10 CFR 35.100,10 CFR 35.200               |
| Shawn R. Kenney, M.D.                   | 10 CFR 31.11,10 CFR 35.100,10 CFR 35.200  |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:  
030-31379Amendment No. 42  
(Corrected Copy)Authorized User (M.D.,D.O.,etc.)Material and Use

A. Arif Khalil, M.D.	10 CFR 35.200
Akram Kholoki, M.D.	10 CFR 35.100,10 CFR 35.200
Sorin Lazar, M.D.	10 CFR 35.200
Jonathon T. Lee, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200
Mary Nicholson, M.D.	10 CFR 35.100,10 CFR 35.200
Omar Obaid, M.D.	10 CFR 35.100,10 CFR 35.200
Charles-Lauwanga Okoro, D.O.	10 CFR 35.200
Harish Patlolla, M.D.	10 CFR 35.200
Anas Hakam Safadi, M.D.	10 CFR 35.200
Michele Semin, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)
Harish Shah, M.D.	10 CFR 35.100,10 CFR 35.200
Vijah P. Shah, M.D.	10 CFR 35.100,10 CFR 35.200
Justin Spackey, M.D.	10 CFR 35.100,10 CFR 35.200
Lingyun Xiong, M.D.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)
Ramana Yedavalli, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)
Kais J. Yehyawi, M.D.	10 CFR 35.100,10 CFR 35.200
Feng Zhang, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)


13. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all glass microspheres received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:  
030-31379Amendment No. 42  
(Corrected Copy)

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 28, 2015 (ML15218A568)
  - B. Letter dated January 6, 2016 (ML16007A729)
  - C. Letter dated January 5, 2017 (ML17018A414)
  - D. Letter dated May 22, 2017 (ML17146B324)
  - E. Letter dated June 20, 2017 (ML17172A121)
  - F. Letter dated September 28, 2017 (ML17276B167)
  - G. Letter dated December 19, 2017 (ML17354A646)



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:  
030-31379Amendment No. 42  
(Corrected Copy)

- H. Letter dated December 19, 2017 (ML17353A894)
- I. Letter dated February 26, 2018 (ML18057A559)
- J. Letter dated September 26, 2019 (ML19270H110)
- K. Letter dated May 11, 2020 (ML20141L681)
- L. Letter dated August 10, 2020 (ML20227A262)
- M. Letter dated September 9, 2020 (ML20260H261)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 17, 2022

By: \_\_\_\_\_

Magdalena R. Gryglak  
Region 3